CPT 90662: Influenza Vaccine, Split Virus, Preservative-Free, High Antigen

CPT code 90662 represents a preservative-free, split-virus influenza vaccine with higher antigen content formulated to enhance immune response; it is given by intramuscular injection. This code is important nationally because seasonal and pandemic influenza vaccination programs rely on accurately coded immunizations for public health reporting, provider reimbursement, and vaccine coverage monitoring. Vaccines with higher antigen content are particularly relevant for populations where improved immunogenicity is clinically desirable.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how CPT code 90662 maps to clinical use, typical sites of service for administration, common billing modifiers associated with immunizations, and payer coverage considerations. The publication outlines billing benchmarks, coding best practices for documentation, and recent policy updates affecting vaccine reimbursement and billing workflows at a national level.

The content provides clinical context for the vaccine product, clarifies service line placement (immunization/injection), and summarizes operational implications for billing teams and immunization clinics. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 90662 describes an influenza vaccine that is a split virus formulation, preservative-free, and contains enhanced antigen content for increased immunogenicity. The product is intended for active immunization against influenza and is administered as an intramuscular injection.

Service Type: Vaccination / Immunization Injection

Typical Site of Service: Outpatient clinic, physician office, pharmacy immunization area, or other ambulatory care settings

Clinical Context

A 72-year-old community-dwelling adult presents to a primary care clinic during influenza season for routine immunization. The clinician confirms eligibility for high-dose, preservative-free, split-virus influenza vaccine based on age and medical history. After screening for contraindications (eg, severe egg allergy, acute febrile illness), the patient receives the vaccine administered intramuscularly in the deltoid. Documentation includes the vaccine product lot number, manufacturer, dose, route (intramuscular), site (right deltoid), date of administration, informed consent verbalized, and any observed immediate reactions for 15 minutes. The clinical workflow includes nurse intake and screening, vaccine preparation per manufacturer instructions, administration by a licensed clinician (RN, NP, PA, or physician), documentation in the electronic medical record and immunization registry, and updating billing with 90662 and appropriate modifier if indicated (for example, facility-only or professional component scenarios). Typical sites of service are outpatient primary care clinics, community health centers, employer-sponsored on-site clinics, long-term care facilities, and pharmacy-based clinics that employ or contract licensed vaccinators.

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, separately identifiable E/M service by the same physician on the same day	Use when a medically significant evaluation and management visit is performed on the same day as vaccine administration and is documented separately.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Family Medicine	Common primary care providers administering adult influenza vaccines.
`207R00000X`	Internal Medicine	Internists frequently provide influenza vaccination to adult and geriatric patients.
`283Q00000X`	Nurse Practitioner	NPs routinely administer vaccines in outpatient and clinic settings.
`367500000X`	Physician Assistant	PAs commonly provide vaccinations in primary care and urgent care clinics.
`333600000X`	Registered Nurse	RNs administer vaccines in clinic, pharmacy, and long-term care settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z23`	Encounter for immunization	Primary diagnosis used when the patient encounters the healthcare system for routine influenza vaccination.
`J00`	Acute nasopharyngitis [common cold]	If mild upper respiratory infection symptoms are present, clinician documents and screens before vaccination; acute moderate-severe illness may defer vaccination.
`Z71.89`	Other specified counseling	Used when vaccine counseling beyond routine consent is documented (eg, detailed vaccine risk/benefit discussion).
`Z98.89`	Other specified postprocedural states	May be used for documentation of prior surgical/status considerations that impact vaccine administration site or technique.
`Z91.21`	Patient's documented physical allergy to contrast media	Example of an allergy code; clinicians screen for allergies relevant to vaccine components and document contraindications or precautions.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`90471`	Immunization administration (includes counseling when performed) single vaccine	Used to report the act of vaccine administration when billing vaccination administration separately from vaccine product.
`90472`	Each additional vaccine administration (same encounter)	Used when more than one injectable vaccine is administered during the same encounter.
`90686`	Influenza virus vaccine, quadrivalent, preservative-free, split virus, 0.5 mL dosage	Alternative influenza vaccine product; may be used when a different formulation is administered instead of `90662`.
`90732`	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23)	Commonly administered during the same visit for older adults to provide broader respiratory infection prevention.
`G0008`	Administration of influenza vaccine (Medicare)	Medicare-specific administration code sometimes used for billing influenza vaccine administration for beneficiaries when applicable.

OpenPayer

Summary & Overview